参考文献
[1] Ndumele CE, Neeland IJ, Tuttle KR, et al. A synopsis of the evidence for the science and clinical management of cardiovascular‑kidney‑metabolic (ckm) syndrome: a scientific statement from the American Heart Association[J]. Circulation, 2023, 148(20):1636‑1664. DOI: 10.1161/CIR.0000000000001186.
[2] Tian Y, Qiu Z, Wang F, et al. Associations of diabetes and prediabetes with mortality and life expectancy in China: A national study[J]. Diabetes Care, 2024, 47(11):1969‑1977. DOI: 10.2337/dca24‑0012.
[3] Bragg F, Halsey J, Guo Y, et al. Blood pressure and cardiovascular diseases in Chinese adults with type 2 diabetes: A prospective cohort study[J]. Lancet Reg Health West Pac, 2021,7:100085. DOI: 10.1016/j.lanwpc.2020.100085.
[4] Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study[J]. BMJ, 2000, 321(7258):412‑419. DOI: 10.1136/bmj.321.7258.412.
[5] Climie RE, van Sloten TT, Bruno RM, et al. Macrovasculature and microvasculature at the crossroads between type 2 diabetes mellitus and hypertension[J]. Hypertension,2019,73(6):1138‑1149. DOI: 10.1161/HYPERTENSIONAHA.118.11769.
[6] Chen G, McAlister FA, Walker RL, et al. Cardiovascular outcomes in framingham participants with diabetes: the importance of blood pressure[J]. Hypertension,2011,57(5):891‑897. DOI: 10.1161/HYPERTENSIONAHA.110.162446.
[7] American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes‑2024[J]. Diabetes Care, 2024,47(Suppl 1):S158‑S178. DOI: 10.2337/dc24‑S009.
[8] Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for obesity treatment and diabetes prevention[J]. N Engl J Med, 2024. DOI: 10.1056/NEJMoa2410819.
[9] Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: The SURPASS‑5 randomized clinical trial[J]. JAMA, 2022, 327(6):534‑545. DOI: 10.1001/jama.2022.0078.
[10] Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT‑2): a double‑blind, randomised, multicentre, placebo‑controlled, phase 3 trial[J]. Lancet, 2023, 402(10402):613‑626. DOI: 10.1016/S0140‑6736(23)01200‑X.
[11] Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity[J]. N Engl J Med, 2022, 387(3):205‑216. DOI: 10.1056/NEJMoa2206038.
[12] Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity[J]. N Engl J Med, 2025, 392(5):427‑437. DOI: 10.1056/NEJMoa2410027.
[13] Heerspink H, Sattar N, Pavo I, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS‑4 trial: post‑hoc analysis of an open‑label, randomised, phase 3 trial[J]. Lancet Diabetes Endocrinol, 2022, 10(11):774‑785. DOI: 10.1016/S2213‑8587(22)00243‑1.
[14] Liu J, Li Y, Ge J, et al. Lowering systolic blood pressure to less than 120 mmHg versus less than 140 mmHg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open‑label, blinded‑outcome, randomised trial[J]. Lancet, 2024, 404(10449):245‑255. DOI: 10.1016/S0140‑6736(24)01028‑6.
[15] 中国高血压防治指南修订委员会,高血压联盟(中国),中国医疗保健国际交流促进会高血压分会,等.中国高血压防治指南(2024年修订版)[J].中华高血压杂志,2024, 32(7):603‑700.DOI:10.16439/j.issn.1673‑7245.2024.07.002.
[16] Buse JB, Bain SC, Mann J, et al. Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the LEADER trial[J]. Diabetes Care, 2020, 43(7):1546‑1552. DOI: 10.2337/dc19‑2251.
[17] Cherney D, Cooper ME, Tikkanen I, et al. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin[J]. Kidney Int, 2018, 93(1):231‑244. DOI: 10.1016/j.kint.2017.06.017.
[18] Weber MA, Mansfield TA, Cain VA, et al. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double‑blind, placebo‑controlled, phase 3 study[J]. Lancet Diabetes Endocrinol, 2016, 4(3):211‑220. DOI: 10.1016/S2213‑8587(15)00417‑9.
[19] Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP 3 randomized clinical trial[J]. JAMA, 2021, 325(14):1403‑1413. DOI: 10.1001/jama.2021.1831.
[20] Jabbour SA, Frías JP, Guja C, et al. Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION‑8 study[J]. Diabetes Obes Metab,2018,20(6):1515‑1519. DOI: 10.1111/dom.13206.
[21] Furtado R, Raz I, Goodrich EL, et al. Efficacy and safety of dapagliflozin in type 2 diabetes according to baseline blood pressure: observations from DECLARE‑TIMI 58 trial[J]. Circulation, 2022, 145(21):1581‑1591. DOI: 10.1161/CIRCULATIONAHA.121.058103.
[22] Serenelli M, Böhm M, Inzucchi SE, et al. Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA‑HF)[J]. Eur Heart J, 2020, 41(36):3402‑3418. DOI: 10.1093/eurheartj/ehaa496.
[23] Leiter LA, Yoon KH, Arias P, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double‑blind, phase 3 study[J]. Diabetes Care, 2015, 38(3):355‑364. DOI: 10.2337/dc13‑2762.
[24] Rosenstock J, Frias J, Páll D, et al. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)[J]. Diabetes Obes Metab, 2018, 20(3):520‑529. DOI: 10.1111/dom.13103.
[25] Lu J, Fu L, Li Y, et al. Henagliflozin monotherapy in patients with type 2 diabetes inadequately controlled on diet and exercise: A randomized, double‑blind, placebo‑controlled, phase 3 trial[J]. Diabetes Obes Metab, 2021, 23(5):1111‑1120. DOI: 10.1111/dom.14314.
[26] Weng J, Zeng L, Zhang Y, et al. Henagliflozin as add‑on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‑blind, placebo‑controlled, phase 3 trial[J]. Diabetes Obes Metab, 2021, 23(8):1754‑1764. DOI: 10.1111/dom.14389.
[27] McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension[J]. Eur Heart J,2024,45(38):3912‑4018. DOI: 10.1093/eurheartj/ehae178.
[28] Witkowski A, Prejbisz A, Florczak E, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea[J]. Hypertension, 2011, 58(4):559‑565. DOI: 10.1161/HYPERTENSIONAHA.111.173799.
[29] Kresoja KP, Rommel KP, Fengler K, et al. Renal sympathetic denervation in patients with heart failure with preserved ejection fraction[J]. Circ Heart Fail, 2021, 14(3):e007421. DOI: 10.1161/CIRCHEARTFAILURE.120.007421.
[30] Schmieder RE. Renal denervation: where do we stand and what is the relevance to the nephrologist?[J]. Nephrol Dial Transplant,2022,37(4):638‑644. DOI: 10.1093/ndt/gfaa237.
[31] Hering D, Marusic P, Duval J, et al. Effect of renal denervation on kidney function in patients with chronic kidney disease[J]. Int J Cardiol, 2017,232:93‑97. DOI: 10.1016/j.ijcard.2017.01.047.
[32] Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter‑Society Consensus; and Vascular Disease Foundation[J]. Circulation, 2006, 113(11):e463‑e654. DOI: 10.1161/CIRCULATIONAHA.106.174526.
[33] 中华医学会肝病学分会,范建高,南月敏,等.代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J].实用肝脏病杂志. 2024, 27(4):494‑510.DOI:10.3760/cma.j.cn501113‑20240327‑00163.
[34] 中华医学会眼科学分会眼底病学组,中国医师协会眼科医师分会眼底病学组. 我国糖尿病视网膜病变临床诊疗指南(2022年)[J].中华眼底病杂志,2023, 39(2):99‑124.DOI:10.3760/cma.j.cn511434‑20230110‑00018.
[35] 中华预防医学会公共卫生眼科学分会. 中国糖尿病视网膜病变远程医疗专家共识(2023年) [J]. 中华眼科杂志. 2023, 59(11):870‑879.DOI:10.3760/cma.j.cn112142‑20230301‑00074.
[36] Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes[J]. Eur Heart J,2024,45(36):3415‑3537. DOI: 10.1093/eurheartj/ehae177.
[37] 中国卒中学会,中国卒中学会神经介入分会,中华预防医学会卒中预防与控制专业委员会介入学组. 急性缺血性卒中血管内治疗中国指南2023[J]. 中国卒中杂志,2023, 18(6):684‑711.DOI:10.3969/j.issn.1673‑5765.2023.06.010.
[38] 中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023年)[J]. 中华心血管病杂志,2023, 51(3): 221‑255. DOI:10.3760/cma.j.cn112148‑20230119‑00038.
[39] Kernan WN, Viscoli CM, Dearborn JL, et al. Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction[J]. JAMA Neurol,2017,74(11):1319‑1327. DOI: 10.1001/jamaneurol.2017.2136.
[40] Jiang Z, Liu L, Bundhun PK. Cardiovascular outcomes observed with ticagrelor versus clopidogrel in type 2 diabetes mellitus patients with acute coronary syndrome: a meta‑analysis[J]. Diabetes Ther,2023,14(2):387‑399. DOI: 10.1007/s13300‑022‑01354‑5.
[41] 《中成药治疗优势病种临床应用指南》标准化项目组. 中成药治疗冠心病临床应用指南(2020年) [J]. 中西医结合心脑血管病杂志, 2021, 19(9):1409‑1435.DOI:10.12102/j.issn.1672‑1349.2021.09.001.
[42] Yang Y, Li X, Chen G, et al. Traditional chinese medicine compound (Tongxinluo) and clinical outcomes of patients with acute myocardial infarction: The CTS‑AMI Randomized Clinical Trial[J]. JAMA, 2023, 330(16):1534‑1545. DOI: 10.1001/jama.2023.19524.
[43] Solomon SD, McMurray J, Vaduganathan M, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction[J]. N Engl J Med, 2024, 391(16):1475‑1485. DOI: 10.1056/NEJMoa2407107.
[44] Desai AS, Vaduganathan M, Claggett BL, et al. Finerenone in patients with a recent worsening heart failure event: The FINEARTS‑HF Trial[J]. J Am Coll Cardiol,2025,85(2):106‑116. DOI: 10.1016/j.jacc.2024.09.004.
[45] Butler J, Shah SJ, Petrie MC, et al. Semaglutide versus placebo in people with obesity‑related heart failure with preserved ejection fraction: a pooled analysis of the STEP‑HFpEF and STEP‑HFpEF DM randomised trials[J]. Lancet, 2024, 403(10437):1635‑1648. DOI: 10.1016/S0140‑6736(24)00469‑0.
[46] Cheang I, Yao W, Zhou Y, et al. The traditional Chinese medicine Qiliqiangxin in heart failure with reduced ejection fraction: a randomized, double‑blind, placebo‑controlled trial[J]. Nat Med, 2024, 30(8):2295‑2302. DOI: 10.1038/s41591‑024‑03169‑2.
[47] Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation,2022,145(18):e895‑e1032. DOI: 10.1161/CIR.0000000000001063.
[48] Nuffield Department of Population Health Renal Studies Group,SGLT2 inhibitor Meta‑Analysis Cardio‑Renal Trialists′ Consortium. Impact of diabetes on the effects of sodium glucose co‑transporter‑2 inhibitors on kidney outcomes: collaborative meta‑analysis of large placebo‑controlled trials[J]. Lancet,2022,400(10365):1788‑1801. DOI: 10.1016/S0140‑6736(22)02074‑8.
[49] Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease[J]. Kidney Int,2024,105(4S):S117‑S314. DOI: 10.1016/j.kint.2023.10.018.
[50] Chen JJ, Wu CY, Jenq CC, et al. Association of glucagon‑like peptide‑1 receptor agonist vs dipeptidyl peptidase‑4 inhibitor use with mortality among patients with type 2 diabetes and advanced chronic kidney disease[J]. JAMA Netw Open, 2022, 5(3):e221169. DOI: 10.1001/jamanetworkopen.2022.1169.
[51] Xu Y, Fu EL, Clase CM, et al. GLP‑1 receptor agonist versus DPP‑4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type‑2 diabetes[J]. Kidney Int, 2022, 101(2):360‑368. DOI: 10.1016/j.kint.2021.10.033.
[52] Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes[J]. N Engl J Med, 2024, 391(2):109‑121. DOI: 10.1056/NEJMoa2403347.
[53] Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease[J]. Kidney Int,2021,99(3S):S1-S87. DOI: 10.1016/j.kint.2020.11.003.
[54] Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease[J]. Kidney Int,2020 ,98(4S):S1-S115. DOI: 10.1016/j.kint.2020.06.019.
[55] Leon SJ, Whitlock R, Rigatto C, et al. Hyperkalemia-related discontinuation of renin-angiotensin-aldosterone system inhibitors and clinical outcomes in CKD: A population-based cohort study[J]. Am J Kidney Dis,2022,80(2):164-173. DOI: 10.1053/j.ajkd.2022.01.002.
[56] Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease[J]. Kidney Int, 2022, 102(5S):S1‑S127. DOI: 10.1016/j.kint.2022.06.008.
[57] Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis[J]. Eur Heart J, 2022, 43(6):474‑484. DOI: 10.1093/eurheartj/ehab777.
[58] Loomba R, Hartman ml, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction‑associated steatohepatitis with liver fibrosis[J]. N Engl J Med, 2024, 391(4):299‑310. DOI: 10.1056/NEJMoa2401943.
[59] Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis[J]. N Engl J Med, 2010, 362(18):1675‑1685. DOI: 10.1056/NEJMoa0907929.
[60] European Association for the Study of the Liver (EASL), (EASD) EAftSoD, European Association for the Study of Obesity (EASO). EASL‑EASD‑EASO Clinical Practice Guidelines on the management of metabolic dysfunction‑associated steatotic liver disease (MASLD)[J]. J Hepatol, 2024, 81(3):492‑542. DOI: 10.1016/j.jhep.2024.04.031.
[61] Wang B, Wang F, Zhang Y, et al. Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta‑analysis[J]. Lancet Diabetes Endocrinol, 2015,3(4):263‑274. DOI: 10.1016/S2213‑8587(14)70256‑6.
[62] Yen FS, Wei JC, Yu TS, et al. Sodium‑glucose cotransporter 2 inhibitors and risk of retinopathy in patients with type 2 diabetes[J]. JAMA Netw Open, 2023, 6(12):e2348431. DOI: 10.1001/jamanetworkopen.2023.48431.
[63] Kataoka SY, Lois N, Kawano S, et al. Fenofibrate for diabetic retinopathy[J]. Cochrane Database Syst Rev, 2023, 6(6):CD013318. DOI: 10.1002/14651858.CD013318.pub2.
[64] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)(上)[J].中国实用内科杂志, 2021,41(8):668‑695. DOI:10.19538/j.nk2021080106.
[65] 中华预防医学会疫苗与免疫分会. 主要慢性病人群流感疫苗和肺炎球菌疫苗接种专家共识[J]. 中国疫苗和免疫,2021, 27(6):711‑742.DOI:10.19914/j.CJVI.2021130.
[66] 中国健康促进与教育协会. 成人预防接种服务专家共识(2023年版)[J]. 中华预防医学杂志, 2024, 58(3):275‑284.DOI:10.3760/cma.j.cn112150‑20240129‑00098.